Oncolytic Virotherapy for human malignant mesothelioma: recent advances - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Oncolytic Virotherapy Year : 2015

Oncolytic Virotherapy for human malignant mesothelioma: recent advances


Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their ability to induce antitumor immune responses. In this review, we summarize preclinical and clinical data regarding the targeting of malignant mesothelioma (MM) by oncolytic viruses. We also discuss the potential of other oncolytic viruses that have already shown antitumor effects against several malignancies in advanced clinical trials but are yet to be tested against MM cells. Finally, we review how the activation of the immune system and combinations with other types of anticancer treatments could support the development of oncolytic virotherapy for the treatment of MM.
Fichier principal
Vignette du fichier
OV-66091-oncolytic-virotherapy-for-human-malignant-mesothelioma--rece_091015 (1).pdf (233.42 Ko) Télécharger le fichier
2015-N BOISGERAULT-Onc Vir_Review.pdf (232.12 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Origin : Files produced by the author(s)

Dates and versions

inserm-01285355 , version 1 (09-03-2016)



Nicolas Boisgerault, Carole Achard, Laurent Cellerin, Frédéric Tangy, Marc Grégoire, et al.. Oncolytic Virotherapy for human malignant mesothelioma: recent advances. Oncolytic Virotherapy, 2015, ⟨10.2147/OV.S66091⟩. ⟨inserm-01285355⟩
210 View
720 Download



Gmail Facebook Twitter LinkedIn More